Collectively, the results of this investigation support the hypothesis that treatment with the SGLT2 inhibitor, DAPA, improves cardiac dysfunction function in the setting of MetS, diabetes, or obesity even in the little effect on high blood glucose and insulin resistance. Here, SLC5A2 is linked to diabetes mellitus.